Those who applied for
Congratulations to everyone who applied for the free trial.
※ For those who missed the “COVID-19 treatment,” don’t worry. We are going out strong once again.
※ Finally starting. InnoTherapy(246960) follow-up stock hits the daily limit price on Tuesday ※
It has been found that interferon response disorder was the cause of sudden deaths among young and healthy people due to COVID-19. Interferon is a glycoprotein produced inside cells invaded by viruses, and it has the ability to suppress viral infection and replication!!
Scientists are researching interferon-based therapies. If a lack of interferon can worsen the disease, conversely, having it in abundance may reduce the likelihood of the disease progressing to a severe stage!!
“I applied and bought small amounts daily for 3 days, and I was really surprised that I made daily limit price profits every day. It’s amazing how this is possible. It’s been about 3 months since I paid the membership fee and received VIP service, and already 30 million KRW has accumulated in my account. Really thankful again and again. Ah! I am also actively recommending it to my acquaintances.” (VIP office worker Yoo Jin Lee, 41 years old)
▶▶ “September 29 daily limit price” offered only until today and then closed.
[Receive ‘severe COVID-19 interferon deficiency’ related stocks!] ▶Receive stocks◀
Think of this as the last chance. If you miss this opportunity, you have to give up.
Exactly on “September 29” it will explode! Don’t miss out and regret it, buy even just 1 million KRW!
▶▶ Only 30 people will be given. “Tuesday daily limit price”! ▶Receive now◀
※ First-come, first-served 30 people closed! Both early and late rounds are over. The hero of the final injury time winning goal ※
[Today’s stocks of interest]
#CKH #UnitedPharma #ShinpoongPharma #Komipharm #IlyangPharma
※ This content is unrelated to the editorial direction of Asia Economy, and all responsibility lies with the information provider.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
